Searchable abstracts of presentations at key conferences in endocrinology

ea0022p424 | Endocrine tumours &amp; neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Serum concentration of o,p’DDD (mitotane), o,p’DDA and o,p’DDE as predictors of tumour response in adrenocortical carcinoma: results of a retrospective European Network for the Study of Adrenal Tumors (ENS@T) multicentre study

Hermsen Ilse , Fassnacht Martin , Terzolo Massimo , Houterman Saskia , Hartigh Jan den , Leboulleux Sophie , Daffara Fulvia , Allolio Bruno , Berruti Alfredo , Chadarevian Rita , Haak Harm , Baudin Eric

Introduction: O,p’DDD is the drug of choice for patients with adrenocortical carcinoma (ACC). Monitoring o,p’DDD serum level has been proposed as predictor of tumour response. Measurement of o,p’DDD metabolites involved in the active pathway may provide an improved prediction of o,p’DDD activity. The objective of our study was to (1)to confirm the currently used threshold o,p’DDD serum level of 14mg/l for achieving a tumour response and (2)compare the ...

ea0020p182 | Endocrine tumours and neoplasia | ECE2009

Endocrine gland-derived vascular endothelial growth factor and its receptors in adrenocortical carcinoma

Sbiera Silviu , Kuehner Dorothee , Wortmann Sebastian , Adam Patrick , Voelker Hans-Ullrich , Kraus Luitgard , Beyer Melanie , Quinkler Markus , Willenberg Holger , Weismann Dirk , Hahner Stefanie , Allolio Bruno , Fassnacht Martin

Objectives: Endocrine gland-derived vascular endothelial growth factor (EG-VEGF; also termed prokineticin-1) has been identified as a mitogen preferable for the endothelium of steroidogenic glands (1). EG-VEGF and its receptors (prokineticin receptors 1 and 2; PKR1 and 2) are highly expressed in the normal adrenal gland and an autocrine mitogenic loop has been proposed (2). Therefore, we investigated the expression of EG-VEGF and its receptors in adrenocortical carcinoma (ACC)...

ea0020p194 | Endocrine tumours and neoplasia | ECE2009

Impact of surgery on clinical outcome in patients with recurrence of adrenocortical carcinoma

Erdogan Ilknur , Hahner Stefanie , Johanssen Sarah , Fenske Wiebke , Quinkler Marcus , Willenberg Holger S , Beuschlein Felix , Brix David , Allolio Bruno , Fassnacht Martin

Introduction: The role of surgery for recurrent ACC is not well defined. Therefore, we used the German ACC Registry to evaluate treatment modalities after first recurrence in patients amenable to surgery.Methods: Patients with recurrence after radical resection and follow-up data were included. Patients with extensive metastasized disease (>2 tumoral organs, peritoneal carcinomatosis) were excluded. Progression-free and overall survival (PFS/OS) were...

ea0016s30.3 | Clinical highlights | ECE2008

[123I]Iodometomidate as a radiotracer for diagnosis of adrenal tumours and adrenocortical carcinoma

Hahner Stefanie , Schirbel Andreas , Kreissl Michael , Fassnacht Martin , Johanssen Sarah , Beuschlein Felix , Quinkler Marcus , Reincke Martin , Stuermer Andrea , Reiners Christoph , Allolio Bruno

Subject: Adrenal tumours (AT) are often detected incidentally and represent a variety of differential diagnoses with variable therapeutic consequences. We have recently developed [123I]Iodometomidate ([123I]IMTO), that specifically binds to adrenal CYP11B enzymes as a SPECT tracer for adrenal scintigraphy. This radiotracer is now evaluated in patients with adrenal tumours in an ongoing clinical trial. The study was approved by the ethical committee and pa...

ea0014p145 | (1) | ECE2007

Epidermal growth factor receptor (EGFR) as a potential new target in the treatment of patients with adrenocortical carcinoma – results of pre-clinical studies

Fassnacht Martin , Hahner Stefanie , Heinrich Barbara , Adam Patrick , Johanssen Sarah , Quinkler Marcus , Koschker Ann-Cathrin , Stroebel Philipp , Marx Alexander , Allolio Bruno

Objectives: Adrenocortical carcinoma (ACC) is a rare malignancy with incompletely understood pathogenesis and poor prognosis. Overexpression of epidermal growth factor receptor (EGFR) has been demonstrated in several tumors and is partly associated with a more aggressive phenotype and a worse prognosis. In addition, targeting the EGFR tyrosine kinase represents a successful new therapeutic strategy, e.g. in non-small cell lung cancer. Therefore, we investigated the role of EGF...

ea0029p790 | Endocrine tumours and neoplasia | ICEECE2012

The influence of surgery in the management of recurrent adrenocortical carcinoma.

Deutschbein T. , Erdogan I. , Jurowich C. , Kroiss M. , Quinkler M. , Langer P. , Willenberg H. , Beuschlein F. , Fottner C. , Klose S. , Heidemeier A. , Brix D. , Fenske W. , Hahner S. , Reibetanz J. , Allolio B. , Fassnacht M.

Objective: The role of surgery for recurrent adrenocortical carcinomas (ACC) is not well defined. Therefore, we evaluated the outcome after surgery for tumor recurrence in patients from the German ACC Registry.Methods: Only patients with first recurrence after initial R0 resection were investigated. Progression–free and overall survival (PFS, OS) after first recurrence were analyzed by Kaplan–Meier method. Cox proportional hazards regression mo...

ea0022oc4.1 | Adrenals | ECE2010

Subtype differentiation in primary hyperaldosteronism: evaluation of alternative algorithms avoiding a controversial gold standard

Lang Katharina , Hahner Stefanie , Vonend O , Rump L C , Quninkler M , Diederich Sven , Maier Katharina , Beuschlein Felix , Bidlingmaier Martin , Endres S , Engelke C , Kickuth Ralph , Fassnacht Martin , Reincke Martin , Allolio Bruno

Context: Primary aldosteronism (PHA) is the most common cause of secondary hypertension. Distinguishing unilateral (UAH) from bilateral (BAH) and other causes of PHA is one of the greatest challenges in the diagnostic process. Adrenal venous sampling (AVS) is widely considered to be the gold standard for subtype differentiation.Methods: Technical and diagnostic outcome of AVS was analysed retrospectively in 59 patients with PHA who underwent AVS at the U...

ea0019oc14 | Neuroendocrine and Steroids | SFEBES2009

Urinary steroid profiling as a biomarker tool for the detection of adrenal malignancy: results of the EURINE ACC Study

Arlt W , Hahner S , Libe R , Hughes BA , Biehl M , Stiekema H , Schneider P , Smith DJ , Shackleton CHL , Opocher G , Bertherat J , Allolio B , Mannelli M , Mantero F , Fassnacht M , Bertagna X , Stewart PM

Adrenal tumours have an incidence of 2–3% in the general population. Adrenocortical carcinoma (ACC), a highly malignant tumor with a poor prognosis, has an annual incidence of two per million but representation in pre-selected patient cohorts with adrenal masses undergoing surgery is up to 12%. Differentiating adrenocortical adenomas (ACA) from ACC represents a continuous challenge, with unfavourable sensitivities and specificities provided by tumour size, imaging criteri...

ea0016p333 | Endocrine tumours | ECE2008

Deficits in the clinical management of patients with adrenocortical carcinoma in Germany

Johanssen Sarah , Koschker Ann-Cathrin , Hahner Stefanie , Quinkler Marcus , Saeger Wolfgang , Morcos Michael , Willenberg Holger , Langer Peter , Klose Silke , Reisch Nicole , Beuschlein Felix , Brauckhoff Michael , Fottner Christian , Wortmann Sebastian , Oelkers Wolfgang , Maeder Uwe , Fassnacht Martin , Allolio Bruno

Adrenocortical carcinoma (ACC) is a rare disease with poor prognosis. Accordingly, in many cases, the attending doctors have no previous experience with the disease. The aim of our study was to evaluate the quality of care in a large number of patients with ACC in Germany. Data from 263 adult patients of the German ACC registry were analyzed with regard to the following parameters: time to diagnosis, hormonal assessment, imaging, histopathological documentation, follow-up. The...

ea0011p471 | Endocrine tumours and neoplasia | ECE2006

The new TNM classification is inferior to the Lee classification in predicting outcome in patients with adrenocortical carcinoma

Fassnacht M , Koschker AC , Hahner S , Maeder U , Weismann D , Linden T , Quinckler M , Willenberg H , Bucsky P , Diehl S , Brauckhoff M , Schaefer M , Schlenz N , Muessig K , Reincke M , Allolio B

Objectives: The TNM classification is a worldwide benchmark for reporting the extent of malignant disease and is intended as a prognostic tool to predict the outcome in patients with cancer. Until 2004, no TNM classification was available for adrenocortical carcinoma (ACC) and different staging systems were used. Due to the rarity of this malignancy, the prognostic value of different staging systems has never been compared directly in a large series of patients.<p class="a...